Digital Sensing Technologies
Validated breath capture
Robust handheld device, simple user workflow, automatic UV cleaning, and quality-control infrastructure for repeatable sampling.
Mobile breath-analysis technology
Breath analysis for clinical and field applications.
Digital Sensing Technologies develops BreathPassTM, a handheld e-Nose platform that captures VOC-patterns in exhaled breath and translates them into research, diagnostic, and operational insight.
Loading 3D model...
BreathPassTM
Drag to rotate
Partner application target
Point-of-care detection
BreathPassTM is a portable breath-analysis platform for situations where fast, non-invasive detection can support earlier decisions, including screening before a patient meets a doctor.
Our pedigree includes development of a COVID-19 recognition algorithm during the pandemic. The same platform can be explored for selected infectious-disease or bacterial targets where breath VOC patterns may support detection-algorithm development.
Alongside our current epilepsy and forensic programs, DST is looking for partners who want to apply BreathPass technology to an application target of their own.
Discuss a partnership
BreathPassTM
Handheld e-Nose device with a simple breath manoeuvre that takes less than 5 seconds.
Mobile workflow
Device paired with a mobile app to manage the test and coach the user through the process.
Cloud + AI
Results can be analyzed in the cloud or on-device using proprietary algorithms infused with AI.
The platform
A real mobile device, built for repeatable breath sampling.
BreathPassTM was originally developed by Deep Sensing Algorithms Ltd in Finland for rapid COVID-19 detection. After the acquisition of DSA in 2024, NewLife Wearables turned the solution into a true platform application and applied focus on new directions: epilepsy seizure prediction, forensic applications, and custom research.
Connected analysis
Cloud-connected analysis and study infrastructure, with the option to run selected analysis on-device where the workflow requires it.
Application algorithms
AI-supported classification models developed for specific physiological and operational questions, not generic sensor sales.
Application focus
Two advanced applications, one shared sensing foundation.
DST is broad by design and separates current advanced applications and a custom research platform.
NewLife Wearables
Epilepsy and seizure prediction
Research is focused on supporting epilepsy diagnosis and identification of VOC patterns that can indicate increased likelihood of seizure.
- Diagnostic breath-profile research
- Seizure prediction hypothesis testing
- Clinical study work with epilepsy centers
DST Forensic Solutions
Forensic screening
The forensic program investigates whether physiological VOC-response patterns can support rapid pre-screening for drug smuggling and carrying of illegal substances in operational environments.
- Customs and border-control workflows
- Fast mobile screening scenarios
- AI-supported classification from breath signatures
Selected partners
Platform access
DST can support selected partners that want to test, validate, license, or co-develop breath-analysis applications on the BreathPass platform.
- Platform leasing for research use
- Technology licensing
- Co-development toward commercialization
Evidence and development
Evidence is developing across clinical and forensic use cases.
DST combines prior BreathPassTM deployment experience with new application-specific studies in epilepsy and forensic screening. Current results support further validation and stepwise regulatory development.
COVID history
BreathPass proof of concept
BreathPassTM was developed for diagnosis of COVID-19 infection. Clinical trials in Hong Kong in 2021 reached 99.9% accuracy for COVID recognition, supporting proof of concept for the technology and AI-based algorithm development.
Epilepsy pilot
PROSE study: the signature of epilepsy in breath
A first pilot study with fewer than 20 patients in two clinics showed that breath profiles of participants with epilepsy could be distinguished from breath profiles of a control group.
Forensic pilot
Drug-packet signatures visible in breath
In a customs-related pilot, breath profiles of positive cases could be separated from control profiles, with CT scan confirmation. A bootstrapping experiment reported average AUC of 0.95 across 500 iterations.
Current studies
Epilepsy validation is under active development.
Current and planned epilepsy work includes studies with Zwolle, SEIN, and Kempenhaeghe. The goal is to move from promising VOC-pattern evidence toward clinically robust endpoints, validated datasets, and a defined regulatory path.
Why breath?
Exhaled breath carries molecular signals from the body.
Breath contains volatile organic compounds that reflect metabolic and physiological processes. Changes in these VOC patterns can provide a fast, repeatable, and patient-friendly route to research and future clinical insight.
For epilepsy, the scientific rationale is reinforced by work with trained dogs: studies have shown that dogs can detect odor signatures associated with epileptic seizures, and later work suggests that some seizure-related odor changes may occur before the event itself. DST is translating that biological signal into a mobile electronic sensing workflow.
Seizures can produce detectable odor signatures
Dog-detection studies support the hypothesis that seizure-related physiological changes can alter body odor. Breath analysis aims to measure related VOC-pattern changes with a scalable device rather than relying on trained animals.
From odor observation to sensor data
BreathPassTM captures sensor responses from exhaled breath and uses analytical models to compare VOC-patterns across patients, controls, time windows, and clinical events.
Regulatory and IP status
A focused path from research evidence to regulated applications.
Research-use status
Epilepsy diagnosis and seizure-prediction applications are currently research use only. They are not yet CE-marked diagnostic or prediction products.
MDR roadmap
BreathPassTM has prior regulated deployment experience in COVID-19 screening. DST is developing its current medical applications toward MDR-compliant clinical validation.
Patent pending
Patent pending protection has been filed around selected breath-analysis applications and platform elements, including sampling, VOC-pattern analysis, environmental compensation, and AI-supported classification workflows.
Responsible claims
Clinical claims will be developed stepwise through study design, endpoint definition, validation datasets, and the applicable regulatory pathway.
Team
The people behind the platform.
DST combines medical technology, data science, AI, engineering, finance, strategy, and scale-up experience.
Maarten Wolleswinkel
Founder
Founder and Chairman of Oaklins and CEO of Physio Medical Systems, with experience as an entrepreneur, serial investor, M&A advisor, and strategist.
Maurik van den Heuvel, PhD
Chief Executive Officer
Medical technology entrepreneur with experience in data science, analytics, AI, strategy consulting, and clinical innovation. Holds a Master in Economics and a PhD in Medicine.
Ank van Elderen
Chief Financial Officer
Finance and business administration leader with multiple CFO roles and a legal background, supporting governance, financing, and operational structure.
Harri Heino
Chief Technology Officer
Former CTO of Deep Sensing Algorithms and R&D Director at Bioretec, with deep experience in engineering, materials science, biomaterials, and medical-device development.
Pekka Rissanen
Technical Director
Former Managing Director of Deep Sensing Algorithms, with experience across engineering, marketing and advertising, and technology strategy.
Collaborations
Company structure
Digital Sensing Technologies, DST and DST Forensic Solutions are trade names of NewLife Wearables BV. BreathPass is a trademark.
NewLife Wearables
Advanced application area focused on epilepsy diagnosis support and seizure-prediction research.
DST Forensic Solutions
Advanced application area focused on breath-based forensic screening and high-throughput operational workflows.
DST platform partnerships
Selective platform leasing, licensing, and co-development for research and commercialization partners.
Contact
Discuss investment, validation, licensing, or forensic applications.
Use the form to create a direct email with the right context.